Darolutamide Shows Less Cognitive Decline Than Enzalutamide in Advanced Prostate Cancer

Every few years, the energy in downtown Chicago shifts during the American Society of Clinical Oncology (ASCO) Annual Meeting. The Magnificent Mile gets a bit more crowded with specialists from across the globe, and the hotels around the Loop fill up with the brightest minds in cancer research. But for the thousands of residents living in the Windy City and the surrounding suburbs—from Naperville to Evanston—the real value of these high-level presentations isn’t in the academic prestige; it’s in the practical, daily reality of surviving and thriving with a diagnosis. This year, a specific set of findings regarding advanced prostate cancer treatment is sparking a necessary conversation about the trade-off between tumor control and cognitive clarity.

The Invisible Side Effect: Brain Fog and the Blood-Brain Barrier

For a long time, the primary goal of treating advanced prostate cancer has been singular: stop the progression of the disease and extend survival. To achieve this, clinicians often turn to Androgen Receptor Pathway Inhibitors (ARPIs). These drugs are powerful, and for many, they are lifesavers. However, as the ARACOG phase 2 study recently highlighted at ASCO 2026, not all ARPIs are created equal when it comes to what happens inside the patient’s head. The study, led by Dr. Alicia Morgans of the Dana-Farber Cancer Institute, directly compared darolutamide (Nubeqa) with enzalutamide (Xtandi), and the results are a wake-up call for patient quality-of-life standards.

The core of the issue lies in the blood-brain barrier—the body’s natural security system that prevents certain toxins and chemicals from entering the brain. It turns out that enzalutamide crosses this barrier at significantly higher levels than darolutamide. When a drug permeates the brain in high concentrations, it can lead to “cognitive decline,” which is a clinical way of saying that patients might experience memory lapses, difficulty concentrating, or a general slowing of thought processes. For a man in his 70s living in Chicago, this isn’t just a data point on a chart; it’s the difference between being able to independently manage a household or navigate the complexities of the CTA and needing a caregiver for basic daily tasks.

The ARACOG trial, which tracked 111 men with various stages of advanced prostate cancer—including nonmetastatic castration-resistant (nmCRPC) and metastatic hormone-sensitive (mHSPC) versions—found that those on darolutamide experienced significantly less cognitive impairment over a 24-week period. While both drugs were similarly effective at controlling the cancer itself, the cognitive “price” paid for that control was notably lower with darolutamide. This suggests that we are entering an era of “precision quality of life,” where the choice of medication is based not just on the tumor’s response, but on the patient’s need to remain mentally sharp.

Why This Matters for the Chicago Medical Landscape

Chicago is home to some of the most sophisticated medical infrastructure in the world, with institutions like Northwestern Memorial Hospital and the University of Chicago Medicine leading the charge in oncological care. However, the sheer size of these “medical cities” can be overwhelming for patients already struggling with cognitive fog. When a patient is dealing with the mental fatigue associated with enzalutamide, the simple act of coordinating appointments across the Streeterville neighborhood or managing the bureaucracy of a major health system can become an insurmountable hurdle.

there is a second-order socio-economic effect here. Cognitive decline in a patient doesn’t happen in a vacuum; it places a massive emotional and financial burden on the family. In the tight-knit communities of the North Shore or the diverse neighborhoods of the South Side, the role of the family caregiver is paramount. If a treatment preserves a patient’s cognitive function, it preserves the family dynamic and reduces the need for premature assisted living interventions. This is why integrating patient advocacy resources into the initial treatment plan is no longer optional—it’s a necessity.

We also have to consider the intersection of oncology, and neurology. Many men diagnosed with advanced prostate cancer are already at a higher risk for age-related cognitive decline or early-stage dementia. Adding a medication that further impairs memory or increases the risk of seizures and falls—as some studies suggest enzalutamide might—creates a dangerous synergy. By opting for a therapy like darolutamide, which has a lower penetration of the blood-brain barrier, clinicians can potentially mitigate these risks, allowing patients to maintain their autonomy for longer.

Navigating the Transition to Cognitive-Friendly Care

If you or a loved one are currently navigating a prostate cancer diagnosis in the Chicago area, the conversation with your oncologist needs to move beyond “Is the tumor shrinking?” and toward “How will this affect my mind?” This requires a multidisciplinary approach. It’s not enough to see one doctor; you need a team that understands the nuances of local healthcare navigation and the specific side-effect profiles of the latest ARPIs.

The Local Resource Guide: Building Your Support Team

Given my background in analyzing healthcare trends and their local impacts, I know that the biggest challenge for Chicagoans isn’t a lack of experts—it’s knowing which *type* of expert to call when the standard treatment starts affecting your quality of life. If you are noticing cognitive shifts or are planning a new treatment regimen, here are the three types of local professionals you should prioritize.

Board-Certified Genitourinary (GU) Oncologists

You don’t just want a general oncologist; you want a specialist who focuses specifically on the urinary tract and male reproductive system. When vetting a GU oncologist at a place like Northwestern or UChicago, ask specifically about their experience with the ARACOG findings and their philosophy on balancing “progression-free survival” with “cognitive preservation.” Look for providers who are active in ASCO and stay current on the latest phase 2 trial data.

Neuro-Oncology Consultants

Since the cognitive effects of ARPIs are essentially a neurological side effect of a cancer drug, a neuro-oncologist is the ideal bridge. These specialists can perform baseline cognitive screenings and monitor for “chemobrain” or drug-induced cognitive decline. Look for consultants who can provide objective memory testing and who can collaborate directly with your primary oncologist to adjust medications if your mental clarity begins to slip.

Certified Patient Navigators & Care Coordinators

Navigating the Loop’s medical complexes while dealing with brain fog is a recipe for stress. A professional patient navigator acts as the “air traffic controller” for your care. Look for navigators who are affiliated with recognized cancer centers or non-profit advocacy groups. They should be able to handle the scheduling, insurance hurdles, and communication between your GU oncologist and your neurologist, ensuring nothing falls through the cracks.

Ready to find trusted professionals? Browse our complete directory of top-rated healthcare providers in the chicago area today.